Issue Information
17 August 2019
17 August 2019
17 August 2019
17 August 2019
17 August 2019
Karen McCulloch, Nicole Romero, Jennifer MacLachlan, Nicole Allard, Benjamin Cowie – 16 August 2019
James M. Paik, Linda Henry, Leyla De Avila, Elena Younossi, Andrei Racila, Zobair M. Younossi – 14 August 2019 – Population‐level nonalcoholic fatty liver disease (NAFLD) death rate data are sparse. We described death rates for adults with NAFLD in the United States using mortality data from the National Vital Statistics System multiple‐cause mortality data (2007‐2016). Decedents who had NAFLD were identified by International Classification of Diseases (ICD) codes K75.81, K76.0, K74.0, K74.6, and K76.9.
Chuanshan Zhang, Renyong Lin, Zhide Li, Shuting Yang, Xiaojuan Bi, Hui Wang, Abudusalamu Aini, Ning Zhang, Abuduaini Abulizi, Cheng Sun, Liang Li, Zhibin Zhao, Rongde Qin, Xiaohong Li, Liang Li, Tuerganaili Aji, Yingmei Shao, Dominique A. Vuitton, Zhigang Tian, Hao Wen – 14 August 2019
Jihane N. Benhammou, Arthur Ko, Marcus Alvarez, Minna U. Kaikkonen, Carl Rankin, Kristina M. Garske, David Padua, Yash Bhagat, Dorota Kaminska, Vesa Kärjä, Jussi Pihlajamäki, Joseph R. Pisegna, Päivi Pajukanta – 14 August 2019 – The global obesity epidemic is driving the concomitant rise in nonalcoholic fatty liver disease (NAFLD). To identify new genes involved in central liver functions, we examined liver RNA‐sequence data from 259 patients who underwent morbidly obese bariatric surgery.
Richard D. Khusial, Catherine E. Cioffi, Shelley A. Caltharp, Alyssa M. Krasinskas, Adina Alazraki, Jack Knight‐Scott, Rebecca Cleeton, Eduardo Castillo‐Leon, Dean P. Jones, Bridget Pierpont, Sonia Caprio, Nicola Santoro, Ayman Akil, Miriam B. Vos – 13 August 2019 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children, but diagnosis is challenging due to limited availability of noninvasive biomarkers.
Rosa Martin Mateos, Agustín Albillos – 13 August 2019 – Bacterial infections are more frequent and severe in patients with advanced liver disease and, therefore, in liver transplant candidates. The increased risk of infection in these patients parallels the severity of the immune dysfunction associated with cirrhosis, which is related to systemic inflammation and progressive immunodeficiency.